Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc.
	Headquarters
Company type	Public
Traded as	Nasdaq: REGN; Nasdaq-100 component; S&P 500 component;
Industry	Pharmaceuticals; Biotech;
Founded	1988
Founders	Leonard Schleifer; George Yancopoulos;
Headquarters	Tarrytown, New York, U.S.
Area served	Global
Key people	Leonard Schleifer (CEO); George Yancopoulos (CSO);
Revenue	US$13.12 billion (2023)
Operating income	US$4.05 billion (2023)
Net income	US$3.95 billion (2023)
Total assets	US$33.08 billion (2023)
Total equity	US$25.97 billion (2023)
Number of employees	13,450 (2023)
Website	www.regeneron.com
	Footnotes / references;

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.^[2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

^ "Regeneron Pharmaceuticals, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 5, 2024.
^ Herper, Matthew (August 14, 2013). "How Two Guys From Queens Are Changing Drug Discovery". Forbes. Archived from the original on March 16, 2014. Retrieved March 22, 2014.

[10K-1] "Regeneron Pharmaceuticals, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 5, 2024.

[herper2013-2] Herper, Matthew (August 14, 2013). "How Two Guys From Queens Are Changing Drug Discovery". Forbes. Archived from the original on March 16, 2014. Retrieved March 22, 2014.

[1]

[2]